Advertisement


S. Vincent Rajkumar, MD, on Advances in Myeloma

2015 ASH Annual Meeting

Advertisement

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes his education session on the evolving diagnostic criteria for myeloma, which focused on smoldering disease and when it becomes an “open flame.”



Related Videos

Leukemia
Lymphoma

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 495).

Lymphoma

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Issues in Oncology

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida. 

Moderator: Robert Rifkin, MD
Participants: Corey Cutler, MD; Pere Gascon, MD, PhD; Mark McCamish, MD, PhD

This program is supported by Sandoz Inc.

Lymphoma

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data (Abstract 254).

Lymphoma

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).

Advertisement

Advertisement




Advertisement